Treatment of multiple sclerosis and related disorders: what's new in the past 2 years?
Noseworthy
John H
JH
Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA. Nswrthy@mayo.edu
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D004673:Encephalomyelitis, Acute Disseminated / Q000628:therapy; D000068717:Glatiramer Acetate; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016899:Interferon-beta / Q000627:therapeutic use; D008775:Methylprednisolone / Q000627:therapeutic use; D008942:Mitoxantrone / Q000627:therapeutic use; D009103:Multiple Sclerosis / Q000145:classification / Q000188:drug therapy / Q000628:therapy*; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000628:therapy; D009462:Neurology / Q000639:trends*; D009471:Neuromyelitis Optica / Q000628:therapy; D010455:Peptides / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D013788:Thalamus / Q000601:surgery
D000276:Adjuvants, Immunologic; D000911:Antibodies, Monoclonal; D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D010455:Peptides; D000068717:Glatiramer Acetate; D016899:Interferon-beta; D008942:Mitoxantrone; D008775:Methylprednisolone